SPRYARS Pharmaceuticals, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−47% vs 200-day) and a crowded short (+21% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −47% vs its 200-day average.
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SPRY is trading
ARS Pharmaceuticals, Inc. is −59% over the past year while the S&P 500 is +16%: 75 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −47%
vs 200-day average · a clear downtrend
- RSI (14)
- 43
RSI (14) · neutral
- Below its 52-week high
- 69%
Below its 52-week high
Details›
- Last close2026-10-23
- $4.03
- 1 monthS&P 500 −0.94%
- −3.2%
- 1 yearS&P 500 +16%
- −59%
- 5 yearsS&P 500 +86%
- −59%
- vs 50-day average$4.81
- −16%
- 52-week high
- $13.06
- 52-week low
- $3.95
- Annualised volatility
- 69%
| Year | Return |
|---|---|
| 2026 (year to date) | −65% |
| 2025 | +10% |
| 2024 | +93% |
| 2023 | −36% |
| 2022 | +28% |
| 2021 | −86% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 2 of 6 | −4.9% |
| Feb | 6 | 3 of 6 | +6.0% |
| Mar | 6 | 2 of 6 | −4.3% |
| Apr | 6 | 2 of 6 | −6.5% |
| May | 6 | 5 of 6 | +3.4% |
| Jun | 6 | 3 of 6 | +5.9% |
| Jul | 6 | 4 of 6 | +3.7% |
| Aug | 6 | 3 of 6 | −3.8% |
| Sep | 6 | 1 of 6 | −22% |
| Oct | 6 | 2 of 6 | −2.9% |
| Nov | 5 | 2 of 5 | +4.4% |
| Dec | 5 | 3 of 5 | +8.0% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.